Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Colorectal Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Colorectal Cancer (1365
)
Colon Cancer (172
)
Rectal Cancer (90
)
Colorectal Cancer (1365
)
Colon Cancer (172
)
Rectal Cancer (90
)
›
Associations
(9)
News
Trials
Search handles
@KrishanJethwa
@anu_iris
@pashtoonkasi
Search handles
@KrishanJethwa
@anu_iris
@pashtoonkasi
Filter by
Latest
8ms
During the GI Cancer Committee session, Dr. Thom George provides an update on the GI004 COMMIT study, currently enrolling patients with metastatic adenocarcinoma of the colon or rectum. This is the last session of #NRG2023. @TGeorgeMD (@NRGonc)
8 months ago
Clinical • Metastases
|
NRG2 (Neuregulin 2)
8ms
7/Key Study Findings🔑 🌟Patients >75yr had very🔽low rate (0.2%) of invasive colorectal adenocarcinoma 🦀 🌟Invasive CRC🦀 patients with a life expectancy <10 years: only 1 of 9 received 🦀 treatment 🌟Patients >85yr had⬆️adverse 🚫event rate @ 10 days 🟰⬆️Risk ⬇️Benefit (@Montalvan214)
8 months ago
Clinical • Adverse events
9ms
ALK Mutation is present in 2.81% of @AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence. https://t.co/xqPTiPcovZ @ALKPositiveinc… https://t.co/KcF0yqWyPP (@4baseCare)
9 months ago
Clinical
|
ALK (Anaplastic lymphoma kinase)
|
ALK mutation
10ms
Perplexing but consistent with the finding of our study on neoadjuvant therapy in colon adenocarcinoma (stage II: neoadjuvant was associated with lower OS than resection first; stage III: neoadjuvant ⬆️ OS) @nirhoresh @JCO_ASCO https://t.co/xZuKpbmVPL (@dr_samehhany81)
10 months ago
Clinical
11ms
🔥🔥🔥Awesome overview of the OPERA trial comparing chemoradiation +/- contact orthovoltage brachy boost for patients cT2-3N0-1, < 5cm primary involving < 50% circumference, rectal adenocarcinoma! Thanks @drlw2309 🙏🏽🙏🏽🙏🏽 (@KrishanJethwa)
11 months ago
Clinical
1year
Shout out to @KristenCiombor and @eaonc A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab & Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma Incredible consortium of researchers! @CathyEngMD @VUMCHemOnc NCT04751370 https://t.co/5KggufithS (@fireflyann)
1 year ago
Clinical • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
1year
Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal Adenocarcinoma https://t.co/oIK9OWCxKB via @onclive (@NANETS1)
1 year ago
POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1)
|
POLE mutation • POLD1 mutation
over1year
The largest study on Rectal adenocarcinoma!🔥 Genomic-Transcriptomic analysis of 738 patients Wnt signalling, mAPC higher in upper rectum High expression of L1CAM~ poor outcome Great work @chatila_w @fsanchezvega 🎉🎉🎉 Looking forward to working on this data! @YJanjigianMD (@anu_iris)
over 1 year ago
Clinical
|
L1CAM (L1 cell adhesion molecule)
almost2years
🧵on Dostarlimab ✅Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient ✅PD-1 is a checkpoint protein expressed on activated T cells and interacts with its 2 ligands to inhibit T-cell activation and cytokines production @AndreaCercek @MSKCancerCenter #1 (@Abdelsatar78)
almost 2 years ago
Mismatch repair
|
PD-1 (Programmed cell death 1)
|
MSI-H/dMMR
|
Jemperli (dostarlimab-gxly)
almost2years
Start your morning at #ASCO22 with some 🔥 research by @cancerassassin1. Coming up in 30 mins: The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas compared to colorectal adenocarcinomas. (@ACS_Research)
almost 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
over2years
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab & Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma sponsored by @theNCI for specific Stage II & III patients who have MicroSatellite Instability PI: @KristenCiombor https://t.co/jl2FH1hIMh (@fireflyann)
over 2 years ago
Clinical
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
almost3years
The teams of @fsanchezvega & @DrGarciaAguilar 🔸correlated KRAS mutants with ECM depletion in rectal adenocarcinomas 🔸showed that KRAS signaling in epithelial cancer cells affects the TME by modulating fibroblast activity https://t.co/Ji4SwYcwZ3 #TME, #KRAS (@MolOncology)
almost 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
almost3years
Option for #MSI rectal cancer pts A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab & Short-Course Radiation in #MSI-H/dMMR Locally Advanced #Rectal Adenocarcinoma sponsored by The NCI for Stage II & III patients. PI: @KristenCiombor https://t.co/xBcAJqHWeF (@fireflyann)
almost 3 years ago
Clinical
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
almost3years
Mets colorectal adenoca or mets endometrioid ca in females Ihc..er/ vimentin/ ck20/ cdx2 (@Tanujai50126574)
almost 3 years ago
VIM (Vimentin) • CDX2 (Caudal Type Homeobox 2)
almost3years
MET Amplification is seen in LUAD, GBM, colon adenocarcinoma, esophageal adenocarcinoma, and cutaneous melanoma. Two among numerous trials: Volitinib in Recurrent or Refractory Primary CNS Tumors (NCT03598244), Savolitinib in CRC (NCT03592641). (@anu_iris)
almost 3 years ago
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification
|
Orpathys (savolitinib)
almost3years
What % of mucinous colorectal adenocarcinomas have an NRG-1 fusion? Should all mucinous CRC be tested for NRG-1 fusion? (@manjuggm)
almost 3 years ago
NRG1 (Neuregulin 1)
|
NRG1 fusion
over3years
#ESMO20 very interesting @clacardone “#KRASG12C 🎯 present in ~2️⃣% of @AACR GENIE, ē lung adenocarcinoma, colon adenocarcinoma, non-small cell lung carcinoma, colorectal adenocarcinoma, & adenocarcinoma of unknown primary having the greatest prevalence.” GYN/GU next.@OncoAlert (@pashtoonkasi)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
over3years
I agree with your main point. However disagree with minor point that drugs that may work in a metastatic setting doesn’t automatically mean effective in the adjuvant setting. Case in point. Colon adenocarcinoma with KRAS wild type and lack of efficacy of Cetuximab. (@ChandlerHParkMD)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
Erbitux (cetuximab)
almost4years
This is the shot in the arm that Lung cancer clinical trials needed. Sure there will be failures such as KRAS/NRAS for adjuvant colon adenocarcinomas. However this will ramp up R&D and ramp up clinical trials in lung cancer to earlier stages. (@ChandlerHParkMD)
almost 4 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login